As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Newsweek on MSN13d
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report ClaimsThe FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
KLBK Lubbock on MSN13d
FTC report highlights prescription drug pricing issues in LubbockPrescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback